期刊
MOLECULES
卷 27, 期 18, 页码 -出版社
MDPI
DOI: 10.3390/molecules27185928
关键词
metabolic shift; viral infections; SARS-CoV-2; glycolysis; glycosylation; 2-deoxy-D-glucose; novel analogs
资金
- Moleculin Inc.
- Moleculin Biotech. Inc.
- CNS Pharmaceuticals
Viral infection triggers metabolic changes in cells, particularly an upregulation of glycolysis. The glycolysis inhibitor 2-DG has been studied as an antiviral drug, but its pharmacokinetic properties limit its application.
Viral infection almost invariably causes metabolic changes in the infected cell and several types of host cells that respond to the infection. Among metabolic changes, the most prominent is the upregulated glycolysis process as the main pathway of glucose utilization. Glycolysis activation is a common mechanism of cell adaptation to several viral infections, including noroviruses, rhinoviruses, influenza virus, Zika virus, cytomegalovirus, coronaviruses and others. Such metabolic changes provide potential targets for therapeutic approaches that could reduce the impact of infection. Glycolysis inhibitors, especially 2-deoxy-D-glucose (2-DG), have been intensively studied as antiviral agents. However, 2-DG's poor pharmacokinetic properties limit its wide clinical application. Herein, we discuss the potential of 2-DG and its novel analogs as potent promising antiviral drugs with special emphasis on targeted intracellular processes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据